Athenex Inc. diskutieren
Buy Athenex Inc.
Kursziel gesetzt auf 20,0
For Athenex (ATNX) SunTrust Robinson initiates the shares as a new Buy with a $28 price target. Robinson's analyst notes 'that the company's "lead oral chemotherapy" platform could be a "better option" for some breast cancer patients. The analyst is also positive on the company's experienced large pharma management and claims that Athenex can improve older products with their "chemistry, formulation, and know-how". The analyst adds that her projections are "conservative" in modeling only 10% and 15% penetration into certain markets for oral docetaxel and irinotecan, with "full credit" adding about $92 per share to her price target.' It should be noted that the company has seen frequent and heavy insider buying in its shares throughout the year for what it is worth.
Einschätzung wurde nach dem Ende von Catch the Monkey automatisch beendet.
Buy mit Kursziel 20,0
Buy Athenex Inc.
Buy Athenex Inc.
Sell Athenex Inc.
Buy Athenex Inc.
Buy Athenex Inc.
Buy Athenex Inc.
Buy Athenex Inc.
Buy Athenex Inc.
Sell Athenex Inc.
Buy Athenex Inc.
Neueste Beiträge
OP_Research in The Hackett Group diskutieren